June 09, 2021 | Deborah Kotz
Researchers turn now to see how COVID-19 pandemic affected microbiome in each city
Each city has its own unique microbiome, a “fingerprint” of viruses and bacteria that serves as type of city profile, according to a new study from an international consortium of researchers that included a team from the University of Maryland School of Medicine (UMSOM). The international project, which sequenced and analyzed samples collected from public transit systems and hospitals in 60 cities around the world, was published today in the journal Cell.
The research is considered to be the largest-ever global metagenomic study of urban microbiomes, spanning both the air and the surfaces of multiple cities. It features a comprehensive analysis for all the microbial species identified—including thousands of viruses and bacteria and two newly identified single-cell organisms not found in reference databases.
Study co-author Lynn Schriml, PhD, UMSOM Associate Professor in the Department of Epidemiology & Public Health and Scientist at the Institute for Genome Sciences (IGS), led the study sampling efforts for Baltimore's transit systems. “Baltimore's distinct microbial signature reveals a unique, fascinating, and diverse world, providing insights into geographical variation and previously unknown microbial genomes,” she said.
Added study senior author Christopher Mason, PhD, a professor at Weill Cornell Medicine and the director of the WorldQuant Initiative for Quantitative Prediction: “Every city has its own ‘molecular echo’ of the microbes that define it. If you gave me your shoe, I could tell you with about 90 percent accuracy the city in the world from which you came.”
The study was conducted before the COVID-19 pandemic shut down cities throughout the world, so the researchers are now looking at how the pandemic affected the microbiome fingerprint of each city. “It’s a good question,” Schriml said, “and we are addressing this in follow-up research.” The consortium launched the MetaCOV project in 2020 to investigate the change in urban metagenomes and isolate the presence of the SARS-CoV-2 virus (the virus that causes COVID-19) in urban environments (e.g. ATM machines, wastewater, hospitals, transit systems).
Findings in the latest research are based on an analysis of 4,728 samples from cities on six continents, taken over the course of three years, and represent the first systematic worldwide catalogue of the urban microbial ecosystem. In addition to distinct microbial signatures in various cities, the analysis revealed a core set of 31 species that were found in 97 percent of samples across the sampled urban areas. The researchers identified 4,246 known species of urban microorganisms, but they also found that any subsequent sampling will still likely continue to find species that have never been seen before, which highlights the raw potential for discoveries related to microbial diversity and biological functions awaiting in urban environments.
In the future, the findings also have many potential practical applications, including identifying potential new compounds that can be used as antibiotics and small molecules annotated from biosynthetic gene clusters (BGCs) that have promise for drug development.
Dr. Schriml joined the International Metagenomics and Metadesign of Subways and Urban Biomes (MetaSUB) consortium in 2016 to gain greater insight on urban built environments through studying the composition and variation of microbes across Baltimore and Washington D.C. mass transit systems. The MetaSUB consortium has expanded since then to include projects sampling diverse built environments, including sewers, monuments and hospitals with Dr. Schriml sampling biofilms on the Orpheus Monument at Fort McHenry and the Soldiers' National Monument at Gettysburg in 2018. She had been joined by study co-author Emmanuel Mongodin, PhD, former Assistant Professor of Microbiology and Immunology at UMSOM and IGS faculty member. Last year, he left the UMSOM to become a program director at the National Heart, Lung, and Blood Institute.
“This is a fascinating study, and it is fitting that our researchers played an integral role in identifying the microbiome fingerprint of Baltimore,” said E. Albert Reece, MD, PhD, MBA, Executive Vice President for Medical Affairs, UM Baltimore, and the John Z. and Akiko K. Bowers Distinguished Professor and Dean, University of Maryland School of Medicine. “Basic research is at the core of our medical school mission and using the information we glean will be crucial for improving our global health in the future.”
Cell, Danko et al.: “A global metagenomic map of urban microbiomes and antimicrobial resistance” https://www.cell.com/cell/fulltext/S0092-8674(21)00585-7 DOI: 10.1016/j.cell.2021.05.002
About the University of Maryland School of Medicine
Now in its third century, the University of Maryland School of Medicine was chartered in 1807 as the first public medical school in the United States. It continues today as one of the fastest growing, top-tier biomedical research enterprises in the world -- with 46 academic departments, centers, institutes, and programs, and a faculty of more than 3,000 physicians, scientists, and allied health professionals, including members of the National Academy of Medicine and the National Academy of Sciences, and a distinguished two-time winner of the Albert E. Lasker Award in Medical Research. With an operating budget of more than $1.2 billion, the School of Medicine works closely in partnership with the University of Maryland Medical Center and Medical System to provide research-intensive, academic and clinically based care for nearly 2 million patients each year. The School of Medicine has nearly $600 million in extramural funding, with most of its academic departments highly ranked among all medical schools in the nation in research funding. As one of the seven professional schools that make up the University of Maryland, Baltimore campus, the School of Medicine has a total population of nearly 9,000 faculty and staff, including 2,500 students, trainees, residents, and fellows. The combined School of Medicine and Medical System (“University of Maryland Medicine”) has an annual budget of over $6 billion and an economic impact of nearly $20 billion on the state and local community. The School of Medicine, which ranks as the 8th highest among public medical schools in research productivity (according to the Association of American Medical Colleges profile) is an innovator in translational medicine, with 606 active patents and 52 start-up companies. In the latest U.S. News & World Report ranking of the Best Medical Schools, published in 2021, the UM School of Medicine is ranked #9 among the 92 public medical schools in the U.S., and in the top 15 percent (#27) of all 192 public and private U.S. medical schools. The School of Medicine works locally, nationally, and globally, with research and treatment facilities in 36 countries around the world. Visit medschool.umaryland.edu
Contact
Deborah Kotz
410-706-4255
dkotz@som.umaryland.edu
Related stories
Tuesday, December 20, 2022
COVID Vaccines Prevented 3 Million Deaths in the U.S., New Analysis Finds
In the two years since the first COVID-19 vaccines were given to patients in the U.S., the vaccines had the cumulative effect of preventing 18 million hospitalizations and 3 million deaths. That is based on a new modeling analysis conducted by a researcher at the University of Maryland School of Medicine (UMSOM) and her colleagues. Results of the analysis were published by the Commonwealth Fund.
Wednesday, February 16, 2022
Study Shows New Drug Combination More Effective Against SARS-CoV-2
Researchers at the University of Maryland School of Medicine (UMSOM) and University of Pennsylvania Perelman School of Medicine have identified a powerful combination of antivirals to treat COVID-19. The researchers showed that combining the experimental drug brequinar with either of the two drugs already approved by the U.S. Food and Drug Administration for emergency use, remdesivir or molnupiravir, inhibited growth of the SARS-CoV-2 virus in human lung cells and in mice. Their findings suggest that these drugs are more potent when used in combination than individually.
Wednesday, January 26, 2022
Trial Co-led by University of Maryland School of Medicine Scientist Confirms Safety of “Mix-and-Match” COVID-19 Vaccine Booster Dosing
A University of Maryland School of Medicine (UMSOM), Center for Vaccine Development and Global Health (CVD), expert is co-leading an ongoing study that was pivotal in recommending adults and teens receive booster COVID-19 shots of their choosing starting in fall 2021. The preliminary clinical trial results, reported today in The New England Journal of Medicine, found that is safe and effective to receive boosters that are the same or a different one from the person’s primary vaccine(s).
Thursday, December 16, 2021
Novavax COVID-19 Vaccine Found to be Safe and Effective in Phase 3 Trial Conducted by UM School of Medicine Researchers
An investigational COVID-19 vaccine made by Novavax was found to be 90 percent effective at preventing COVID-19 illness, according to results from a Phase 3 clinical trial published today in the New England Journal of Medicine. The University of Maryland School of Medicine’s (UMSOM) Center for Vaccine Development and Global Health served as one of the trial sites, and Karen Kotloff, MD, Professor of Pediatrics at UMSOM, served as Co-Chair for the trial protocol.
Tuesday, December 14, 2021
UM School of Medicine’s Office of Public Affairs and Communications Honored with 2021 PRSA ‘Best In Maryland’ Award
The University of Maryland School of Medicine (UMSOM)'s Office of Public Affairs & Communications received the Public Relations Society of America (PRSA) 2021 “Best in Maryland Award,” the PRSA’s highest honor, for its COVID-19 Communications program. The award was given at the PRSA Maryland Gala, held on December 9, 2021.
Wednesday, September 08, 2021
UM School of Medicine Reaching Underserved Communities Through Grass Roots Efforts to Increase COVID-19 Vaccination Rates
In an effort to increase COVID-19 vaccination rates among children and families, and ultimately help bring the pandemic under control, the Department of Family & Community Medicine (DFCM) and the Department of Psychiatry at the University of Maryland School of Medicine (UMSOM) are partnering with key community and faith-based groups in Baltimore city to reach the most vulnerable and underserved communities. This partnership will also extend across Maryland, Delaware, Virginia, and West Virginia.
Wednesday, July 07, 2021
UM School of Medicine Researchers Develop Two Rapid Tests for COVID-19 Using Innovative Techniques
Researchers at the University of Maryland School of Medicine (UMSOM) have developed two rapid diagnostic tests for COVID-19 that are nearly as accurate as the gold-standard test currently used in laboratories. Unlike the gold-standard test, which extracts RNA and uses it to amplify the DNA of the virus, these new tests can detect the presence of the virus in as little as five minutes using different methods.
Tuesday, March 16, 2021
New Study Finds Healthcare Settings Do Not Pose Added Risk Factor for Covid-19 Infection Spread Among U.S. Healthcare Personnel
Healthcare personnel who were infected with COVID-19 faced stronger risk factors outside of the workplace than in their hospital or healthcare settings. That is the finding of a new study published today in the Journal of the American Medical association's JAMA Network Open conducted by University of Maryland School of Medicine (UMSOM) researchers and colleagues at the Centers for Disease Control and Prevention (CDC) and three other universities.
Thursday, January 21, 2021
UM School of Medicine Hosted Media Availability for Ensuring Trust in COVID-19 Vaccine Event
On January 22, 2021 at 2 p.m., the University of Maryland School of Medicine (UMSOM) hosted Black faith-based leaders, COVID-19 research volunteers, and “America’s Doctor,” Anthony Fauci, MD. The event provided straight talk about fears, trust issues, and why we need our Black and Brown community to be a part of COVID-19 vaccine research.
Tuesday, January 05, 2021
Dr. Kathleen Neuzil, World-renowned Leader in Vaccine Research, Receives Moderna Vaccine
Kathleen Neuzil, MD, MPH, FIDSA, the Myron M. Levine, MD, DTPH, Professor of Vaccinology and Director of the University of Maryland School of Medicine’s (UMSOM)’s Center for Vaccine Development and Global Health (CVD), received her first injection of the Moderna vaccine for COVID-19 on December 31. Researchers at the University of Maryland School of Medicine (UMSOM) played an integral part in the dedicated work that led to the U.S. Food and Drug Administration issuing an Emergency Use Authorization for the Moderna vaccine in December.
Tuesday, January 05, 2021
University of Maryland School of Medicine Begins Phase 3 Trial of Novavax COVID-19 Vaccine Candidate
Researchers at the University of Maryland School of Medicine (UMSOM) will participate in a Phase 3 clinical trial of an investigational COVID-19 vaccine to protect against SARS-CoV-2, the coronavirus causing COVID-19 that continues to impact millions of people around the world. The clinical trial will test the safety and effectiveness of NVX-CoV2373, being developed by U.S. biotechnology company, Novavax, Inc., based in Gaithersburg, MD.
Thursday, November 19, 2020
Promising Results Seen in Pfizer/BioNTech COVID-19 Vaccine After Phase 1 Trial by University of Maryland School of Medicine
Just six months after beginning a clinical development program that first enrolled here at the University of Maryland School of Medicine (UMSOM), Pfizer and BioNTech report interim results showing an mRNA COVID-19 vaccine had no serious safety concerns and has been found to be 95 percent effective in protecting individuals from COVID-19.
Friday, November 13, 2020
UM School of Medicine and School of Pharmacy Researchers Identify Promising New Compounds to Potentially Treat Novel Coronaviruses
Researchers at the University of Maryland School of Medicine (UMSOM) and School of Pharmacy (UMSOP) have discovered new drug compounds to potentially treat the novel coronavirus that causes COVID-19. The compounds disrupt the functioning of a protein complex inside human cells that the researchers discovered is critical for the replication and survival of coronaviruses. This finding could lead to the development of new broad-spectrum antiviral drugs that target viruses such as influenza, Ebola and coronaviruses, according to a new study published today in the Proceedings of the National Academy of Sciences (PNAS) journal.
Tuesday, June 16, 2020
UM School of Medicine Researchers Receive Federal Funding to Rapidly Test New Treatments for COVID-19
Researchers at the University of Maryland School of Medicine (UMSOM) will be partnering on an agreement funded by the federal government’s Defense Advanced Research Projects Agency (DARPA) to rapidly test hundreds of drugs, approved and marketed for other conditions, to see whether any can be repurposed to prevent or treat COVID-19. The compounds will be tested in studies using state-of-the-art technologies in the laboratory of coronavirus researcher Matthew Frieman, PhD., Associate Professor of Microbiology and Immunology at the University of Maryland School of Medicine. UMSOM will receive up to $3.6 million over the next year to fund this effort.
Tuesday, June 02, 2020
UM School of Medicine’s Institute of Human Virology Awarded Grants to Strengthen COVID-19 Response in Sub-Saharan Africa
The Center for International Health, Education and Biosecurity (Ciheb) at the University of Maryland School of Medicine’s Institute of Human Virology was awarded $4 million from the U.S. Centers for Disease Control and Prevention (CDC) to support coronavirus disease 2019 (COVID-19) response activities in Botswana, Nigeria, Malawi, and Mozambique.
Monday, June 01, 2020
In A COVID-19 World, Another Threat to the Health of Our Children
In the U.S., our children rarely fall ill to grave infections because they are protected by vaccines. Serious illnesses like measles, mumps, congenital rubella syndrome, chickenpox, diphtheria, tetanus, whooping cough, rotavirus diarrhea, hepatitis (A and B), polio and bacterial meningitis are all preventable through routine childhood vaccinations.
Thursday, May 28, 2020
UM School of Medicine Researchers Develop Experimental Rapid COVID-19 Test Using Innovative Nanoparticle Technique
Scientists from the University of Maryland School of Medicine (UMSOM) developed an experimental diagnostic test for COVID-19 that can visually detect the presence of the virus in 10 minutes. It uses a simple assay containing plasmonic gold nanoparticles to detect a color change when the virus is present. The test does not require the use of any advanced laboratory techniques, such as those commonly used to amplify DNA, for analysis. The authors published their work last week in the American Chemical Society’s nanotechnology journal ACS Nano.
Thursday, May 21, 2020
UM School of Medicine Begins First Innovative Trial of Experimental Stem Cell Therapy to Reduce Deaths in Sickest COVID-19 Patients
Researchers at the University of Maryland School of Medicine (UMSOM) have begun testing an experimental stem cell therapy developed by Mesoblast Limited to treat hospitalized COVID-19 patients with moderate to severe acute respiratory distress syndrome (ARDS) who are on ventilators to help them breathe. The trial, which is being conducted at the University of Maryland Medical Center (UMMC) and additional sites across the U.S, will involve a total of 300 patients randomized to receive either the drug remestemcel-L or a placebo in addition to the recommended standard of care to manage severe COVID-19 infections. The first patient in this national trial was treated at UMMC.
Tuesday, May 05, 2020
UM School of Medicine is First in U.S. to Test Unique RNA Vaccine Candidate for COVID-19
In a significant development in the global effort to discover a safe and effective vaccine for COVID-19, researchers at the University of Maryland School of Medicine (UMSOM) became the first in the U.S. to begin testing experimental COVID-19 vaccine candidates developed by Pfizer and BioNTech. The research, funded by Pfizer Inc., will study the safety, efficacy, and dosing of an experimental mRNA -based vaccine.
Thursday, April 23, 2020
UM School of Medicine Researchers Test Remdesivir as Potential Therapy for COVID-19 Patients
Researchers at the University of Maryland School of Medicine (UMSOM) are testing the effectiveness of the investigational antiviral drug remdesivir in hospitalized adult patients with SARS-CoV-2 (COVID-19). The randomized controlled clinical trial is evaluating the safety and effectiveness of the drug, and it is part of a national study funded by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH).
Friday, April 10, 2020
University of Maryland School of Medicine Launches New Large Scale COVID-19 Testing Initiative
University of Maryland School of Medicine (UMSOM) Dean E. Albert Reece, MD, PhD, MBA, announced today the launch of a large-scale COVID-19 Testing Initiative that will significantly expand testing capability over the coming weeks, enabled by new funding of $2.5 million from the State of Maryland.
Thursday, June 13, 2019
UM School of Medicine's J. Kathleen Tracy, PhD, is Named 2019-20 Fellow by the American Council on Education
The American Council on Education (ACE) has announced that J. Kathleen Tracy, PhD, Associate Professor of Epidemiology & Public Health at the University of Maryland School of Medicine (UMSOM), has been named an ACE Fellow for academic year 2019-20. Following nomination by the senior administration of their institutions and a rigorous application process, 39 Fellows were selected this year.
Wednesday, May 29, 2019
The Human Microbiome Project expands the toolbox for studying host and microbiome interactions
New studies provide a framework for future studies of the role of the microbiome in health and disease.
Tuesday, January 23, 2018
Novel Gene Mutations Linked to High HDL Cholesterol and Apparent Protection from Heart Disease
Researchers at the University of Maryland School of Medicine (UMSOM) have uncovered genetic mutations that may explain why people with high levels of high-density lipoprotein (HDL) cholesterol, the “good cholesterol,” have a reduced risk of coronary heart disease.